



Supplemental Figure S1. BZD prescriptions are associated with improved disease-specific pancreatic cancer patient survival. (A) Number of patients by cancer type with a record of BZD prescriptions by cancer type in males (black bar, top) and females (pink bar, bottom). (B) Kaplan Meier curve comparing progression-free survival of pancreatic cancer

patients at Roswell Park from 2004-2020 with a record of chemotherapy with (n=69) or without (n=219) a prescription record of BZDs (excluding midazolam). (C) Kaplan Meier curve comparing disease-specific survival of pancreatic cancer patients at Roswell Park from 2004-2020 with a record of chemotherapy with (n=357) or without (n=1093) a prescription record of BZDs (excluding midazolam). (D) Covariate adjusted analysis evaluating the impact of BZD prescription records on pancreatic cancer patient disease-specific survival accounting for age, sex, race, clinical stage, additional treatments, and progressive disease. (E) Percentage of invasive nevi/melanoma, brain, breast, colon, corpus uteri, head and neck, kidney, ovarian, pancreatic, and prostate cancer patients prescribed BZDs that are receiving midazolam. Statistics: See Figure 1.